February 6, 2022
NIA IMPACT Collaboratory multiple principal investigator Vince Mor, PhD co-authored a commentary article describing the potential for using pragmatic research designs that promote fairness and equity to conduct research studies on the efficacy of anti-amyloid therapies to treat Alzheimer’s disease.
Together, Mor and co-author M. Maria Glymour, ScD, MS express support for the CMS proposal to cover aducanumab the FDA approved treatment for Alzheimer’s disease, only for Medicare beneficiaries that participate in an approved clinical trial. Authors support the decision saying it will result in definitive findings about the treatment benefits in 3–4 years, rather than the decade or more it will take to assess the benefits using an FDA-mandated follow-up study.
Read the full article at this link